€2.48
3.13% yesterday
Xetra, Nov 29, 05:36 pm CET
ISIN
DE0006595101
Symbol
MED
Index

MediClin Target price 2024 - Analyst rating & recommendation

MediClin Classifications & Recommendation:

Buy
100%

MediClin Price Target

Target Price €4.75
Price €2.48
Potential
Number of Estimates 1
1 Analyst has issued a MediClin price target 2025. The average MediClin target price is €4.75. This is higher than the current stock price.
A rating was issued by 1 analysts: 1 Analysts recommend MediClin to buy, 0 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the MediClin stock has an average upside potential 2025 of . Most analysts recommend the MediClin stock at Purchase.

Sales and Margin forecast 2024, 2025 & 2026

Create a premium account to unlock analyst estimates. Learn more

Dec '23 2024
Estimates
Revenue Million € 730.07 730.00
3.60% 0.01%
EBITDA Margin 8.76% 12.43%
15.79% 41.90%
Net Margin -1.50% 2.15%
211.00% 243.68%

1 Analyst has issued a sales forecast MediClin 2024 . The average MediClin sales estimate is

€730m
Unlock
. This is
0.45% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
€730m 0.45%
Unlock
, the lowest is
€730m 0.45%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 €730m 3.60%
2024
€730m 0.01%
Unlock
2025
€752m 3.00%
Unlock
2026
€763m 1.50%
Unlock

1 Analyst has issued an EBITDA forecast MediClin 2024 . The average MediClin EBITDA estimate is

€90.8m
Unlock
. This is
7.52% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
€90.8m 7.52%
Unlock
, the lowest is
€90.8m 7.52%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 €64.0m 12.76%
2024
€90.8m 41.94%
Unlock
2025
€94.6m 4.27%
Unlock
2026
€97.8m 3.38%
Unlock

EBITDA Margin

2023 8.76% 15.79%
2024
12.43% 41.90%
Unlock
2025
12.59% 1.29%
Unlock
2026
12.82% 1.83%
Unlock

The average MediClin net profit estimate is

€15.7m
Unlock
. This is
206.49% higher
Unlock
than the net profit for the last 12 months(TTM).

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 €-10.9m 215.00%
2024
€15.7m 243.52%
Unlock
2025
€18.5m 18.18%
Unlock

Net Margin

2023 -1.50% 211.00%
2024
2.15% 243.68%
Unlock
2025
2.46% 14.42%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 & 2026

Create a premium account to unlock analyst estimates. Learn more

Dec '23 2024
Estimates
Earnings Per Share -0.23 0.33
215.00% 243.48%
P/E 7.52
EV/Sales 0.66

The average MediClin <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

€0.33
Unlock
. This is
206.45% higher
Unlock
than earnings per share in the financial year 2023.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 €-0.23 215.00%
2024
€0.33 243.48%
Unlock
2025
€0.39 18.18%
Unlock

P/E ratio

Current -7.88 227.92%
2024
7.52 195.43%
Unlock
2025
6.36 15.43%
Unlock

Based on analysts' sales estimates for 2024, the MediClin stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 0.66 4.35%
2024
0.66 0.17%
Unlock
2025
0.64 2.91%
Unlock
2026
0.63 1.47%
Unlock

P/S ratio

Current 0.16 7.00%
2024
0.16 0.44%
Unlock
2025
0.16 2.91%
Unlock
2026
0.15 1.47%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today